KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 8.19%.

  • Castle Biosciences' EBITDA Margin fell 141100.0% to 8.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.17%, marking a year-over-year decrease of 98400.0%. This contributed to the annual value of 2.61% for FY2024, which is 335400.0% up from last year.
  • As of Q3 2025, Castle Biosciences' EBITDA Margin stood at 8.19%, which was down 141100.0% from 4.93% recorded in Q2 2025.
  • Castle Biosciences' EBITDA Margin's 5-year high stood at 5.92% during Q3 2024, with a 5-year trough of 91.7% in Q1 2022.
  • Its 5-year average for EBITDA Margin is 27.63%, with a median of 18.76% in 2021.
  • Per our database at Business Quant, Castle Biosciences' EBITDA Margin plummeted by -729400bps in 2022 and then soared by 674900bps in 2024.
  • Castle Biosciences' EBITDA Margin (Quarter) stood at 25.68% in 2021, then crashed by -132bps to 59.55% in 2022, then surged by 86bps to 8.56% in 2023, then skyrocketed by 155bps to 4.69% in 2024, then crashed by -275bps to 8.19% in 2025.
  • Its EBITDA Margin stands at 8.19% for Q3 2025, versus 4.93% for Q2 2025 and 31.74% for Q1 2025.